|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-8-5
|
|
pubmed:abstractText |
High-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was applied to improve the prognosis of patients with high-risk stage 3 neuroblastoma. From January 1997 to December 2006, 28 patients were newly diagnosed as stage 3 neuroblastoma. Nine of 11 patients with N-myc amplification and 5 of 17 patients without N-myc amplification (poor response in 2 patients, persistent residual tumor in 2 and relapse in 1) underwent single or tandem HDCT/ASCR. Patients without high-risk features received conventional treatment modalities only. While 8 of 9 patients underwent single HDCT/ASCR and the remaining one patient underwent tandem HDCT/ASCR during the early study period, all 5 patients underwent tandem HDCT/ASCR during the late period. Toxicities associated with HDCT/ASCR were tolerable and there was no treatment-related mortality. While the tumor relapsed in two of eight patients in single HDCT/ASCR group, all six patients in tandem HDCT/ASCR group remained relapse free. The 5-yr event-free survival (EFS) from diagnosis, in patients with N-myc amplification, was 71.6+/-14.0%. In addition, 12 of 14 patients who underwent HDCT/ASCR remained event free resulting in an 85.1+/-9.7% 5-yr EFS after the first HDCT/ASCR. The present study demonstrates that HDCT/ASCR may improve the survival of patients with high-risk stage 3 neuroblastoma.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-10492635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-10519894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-11027422,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-11027423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-11980999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-12548494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-15017562,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-15659956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-15761876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-1608352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-16129365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-16427213,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-16782928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-17468771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-8336186,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-8823319,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-9060561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-9337055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-9508178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-9552023,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19654949-9716039
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1598-6357
|
|
pubmed:author |
pubmed-author:ChoEun JooEJ,
pubmed-author:KimDae WonDW,
pubmed-author:KimJhingookJ,
pubmed-author:KimJu YounJY,
pubmed-author:KooHong HoeHH,
pubmed-author:LeeSuk KooSK,
pubmed-author:LimDo Hoondo H,
pubmed-author:SuhJung MinJM,
pubmed-author:SuhYeon LimYL,
pubmed-author:SungKi WoongKW,
pubmed-author:YooKeon HeeKH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
660-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19654949-Adolescent,
pubmed-meshheading:19654949-Adult,
pubmed-meshheading:19654949-Child,
pubmed-meshheading:19654949-Combined Modality Therapy,
pubmed-meshheading:19654949-Female,
pubmed-meshheading:19654949-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:19654949-Humans,
pubmed-meshheading:19654949-Male,
pubmed-meshheading:19654949-Middle Aged,
pubmed-meshheading:19654949-Neoplasm Staging,
pubmed-meshheading:19654949-Neuroblastoma,
pubmed-meshheading:19654949-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:19654949-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:19654949-Recombinant Proteins,
pubmed-meshheading:19654949-Survival Rate,
pubmed-meshheading:19654949-Tomography, X-Ray Computed,
pubmed-meshheading:19654949-Transplantation, Autologous
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.
|
|
pubmed:affiliation |
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
